Seeking Novel Therapeutic Approaches for Circadian Rhythm Sleep Disorder (CRSD) and/or Disease-Comorbid Insomnia

This campaign has been commissioned by an international Japanese pharmaceutical company who combat diseases using a combination of ground-breaking technology and biology, with an extensive track record of academic collaboration. They are seeking novel therapeutic approaches for Circadian Rhythm Sleep Disorder (CRSD) and/or disease-comorbid insomnia.

Approaches of Interest

- Clinical development candidate (any modality including small molecules, antibodies, etc.)
- Casein Kinase-1 inhibitor which has clear advantage compared to BIIB-118 (Biogen/Pfizer, Phase 1)
- Clock gene (e.g. Period, Cry, REV-ERB, ROR) targeted programs
- Novel target or mechanism for the treatment of CRSD and/or disease-comorbid insomnia
- All four types of CRSD are within scope (Delayed, Advanced, Irregular, N24)
- Validation through in vivo models (e.g. animal models) is preferred, but in vitro validation is also within scope
- Development of highly predictable or translational preclinical models of CRSD or co-morbid insomnia are of particular interest

Out of Scope

Conventional targets and approaches, e.g. Orexin, melatonin, benzodiazepine, and related sub-receptors.

Developmental Stages of Interest

Research at basic stage through to phase I of clinical trials is within scope, with preclinical research being of highest interest.

Jurisdictions of Interest

Our client is open to opportunities worldwide.